Illumina, Inc.NASDAQ
Advanced Chart
  • Apr. 11, 2012, 5:57 PM

    Swiss drugmaker Roche (RHHBY.PK), in a new letter to Illumina (ILMN) shareholders a week ahead of a shareholders meeting for the maker of genetic analysis equipment, appears to indicate a willingness to raise its $51/share offer. ILMN shares, -1.6% AH, have been trading above $51 and closed at $52.57 today.

    | Apr. 11, 2012, 5:57 PM
  • Apr. 10, 2012, 11:46 AM

    In another blow to Roche’s (RHHBY.PK) hostile grab for gene-sequencing company Illumina (ILMN -0.7%), proxy adviser Glass Lewis recommends shareholders support ILMN’s board in its proxy fight, joining ISS and Egan-Jones. ILMN says it is pleased to have all three well-known shareholder advisers on its side.

    | Apr. 10, 2012, 11:46 AM
  • Apr. 8, 2012, 4:15 AM

    Roche (RHHBY.PK) said on Friday that it remains "willing to consider additional value" to its $6.7B bid for Illumina (ILMN) after receiving a setback from two proxy advisors. Institutional Shareholder Services and Egan-Jones Ratings recommended that shareholders reject Roche's offer and its nominees for the U.S. firm's board.

    | Apr. 8, 2012, 4:15 AM
  • Apr. 4, 2012, 3:50 AM

    Roche (RHHBY.PK) presses on its pursuit of Illumina (ILMN), appealing directly to shareholders in a letter which says its $51/share bid "represents a significant premium to where Illumina would likely trade on a standalone basis and provides certainty of value through an all-cash payment to Illumina's shareholders." (previously)

    | Apr. 4, 2012, 3:50 AM
  • Apr. 2, 2012, 2:28 PM
    Illumina (ILMN -1.2%) says its Board unanimously rejects Roche's (RHHBY.PK +2.3%) revised $51/share takeover offer, claiming the offer still undervalues ILMN and does not adequately reflect the company's singular position in an industry poised for extraordinary growth. (earlier)
    | Apr. 2, 2012, 2:28 PM
  • Apr. 2, 2012, 3:50 AM
    Roche (RHHBY.PK) may drop its $6.7B bid for Illumina (ILMN), according to a report in SonntagsZeitung. Sources say Roche may run out of patience soon and views Illumina as a "nice-to-have" but not a "must-have."
    | Apr. 2, 2012, 3:50 AM
  • Mar. 29, 2012, 10:08 AM
    Roche (RHHBY -0.9%) could up its bid even further if Illumina (ILMN +2%) were to hold talks, according to sources familiar with the situation. The drug giant just raised its bid to $51 a share, but could go higher still if talks were agreed to and Roche saw more value in its business. Roche is facing opposition from Baillie Gifford, Illumina's second-largest shareholder with an 11% stake.
    | Mar. 29, 2012, 10:08 AM
  • Mar. 29, 2012, 7:19 AM

    Shares of Illumina (ILMN) tack on a 2.6% gain premarket to $51.16 after Roche raises its offer to buy the company to $51. JPMorgan doesn't think the action is over and is out with an early morning call for shares to run up to $55.

    | Mar. 29, 2012, 7:19 AM
  • Mar. 29, 2012, 3:49 AM

    Roche (RHHBY.PK) raises its hostile offer for Illumina (ILMN) by 15% to $51/share, or ~$6.7B, hoping to close a deal more quickly with shareholders that have thus far been unimpressed by the perceived lowball offer. Illumina shares closed at $49.88 yesterday, above the initial $44.50/share bid.

    | Mar. 29, 2012, 3:49 AM
  • Mar. 26, 2012, 3:39 AM

    Roche (RHHBY.PK) once again extends its tender offer for Illumina (ILMN), this time to April 20, and keeps the price unchanged at $44.50. Illumina continues to view the offer as "grossly inadequate."

    | Mar. 26, 2012, 3:39 AM
  • Mar. 13, 2012, 6:25 PM

    Roche (RHHBY.PK) says it's received a second request for information from the FTC regarding its proposed acquisition of Illumina (ILMN). The agency is seeking additional information regarding Roche's micro-array business.

    | Mar. 13, 2012, 6:25 PM
  • Feb. 27, 2012, 2:58 AM

    Roche (RHHBY.PK) extends its $44.50/share offer for Illumina (ILMN) until March 23. Illumina, which previously rejected the bid, responds the extension was expected given the low number of shares that have been tendered, a fact which reflects the degree to which Roche's bid undervalues the company.

    | Feb. 27, 2012, 2:58 AM
  • Feb. 9, 2012, 10:03 AM
    Illumina (ILMN +1.1%) trades higher on chatter that an activist investor movement may be afoot and ongoing speculation on the firm's deal with Roche (RHHBY.PK). Trader Karen Finerman dissects the semantics of a recent statement from Roche on its merger bid to translate that the phrase "ready to commence discussions" equates to we’ll pay more.
    | Feb. 9, 2012, 10:03 AM
  • Feb. 7, 2012, 4:13 PM
    Illumina (ILMN) rises 1% AH after declaring Roche's $44.50/share hostile bid to be inadequate, and calling the offer's timing "blatantly opportunistic." Given that Illumina closed today at $51.80, such a response was widely expected. Two weeks ago, Illumina adopted a poison pill in response to Roche's offer.
    | Feb. 7, 2012, 4:13 PM
  • Jan. 31, 2012, 5:43 PM

    It took just three hours for Illumina (ILMN), the target of a hostile $5.7B takeover by Roche (RHHBY.PK), to respond to Roche’s 11 potential nominees to ILMN's board. CEO Jay Flatley has no interest in the “board packing” proposal, and says the current nine board members, including himself, ”will continue to act independently and in the best interests of stockholders."

    | Jan. 31, 2012, 5:43 PM
  • Jan. 26, 2012, 8:20 AM

    Illumina (ILMN) adopts a poison pill in a bid to stop a takeover by Roche (RHHBY.PK). The rights plan is triggered if a 15% ownership target is hit. Shares of ILMN -1.5%.

    | Jan. 26, 2012, 8:20 AM | 2 Comments